Omega-3 Fatty Acids for Cardiovascular Risk Reduction
The cardiovascular story for omega-3s is nuanced: REDUCE-IT showed 4 g/day icosapent ethyl (prescription EPA) cut events 25% in statin-treated high-risk patients, while standard supplement-dose trials (VITAL, ASCEND) were neutral for primary prevention. Triglyceride lowering is reliable at 2–4 g/day.
Overview
Verdict
Prescription high-dose EPA reduced events in high-risk patients (REDUCE-IT); general fish oil supplements have not shown event reduction.
How It Works
Dosing & Protocol
Typical dose
- Recommended dose
- EPA+DHA 1–2 g/day for general support; prescription EPA only under medical care.
- Expected timeframe
- 6–12 weeks for triglycerides; event outcomes over years.
Protocol
- form
- Fish oil or algal oil for general use. The trial that reduced cardiovascular events, REDUCE-IT, used icosapent ethyl - purified EPA ethyl ester at 4 g/day - which is a prescription medicine, not a supplement
- duration
- Years; event reduction is a long-term outcome
- co factor
- Take with a fat-containing meal. Evidence is genuinely mixed and this is one of the more contested areas in cardiology. Large trials of standard-dose fish oil - VITAL at 840 mg/day and ASCEND at 840 mg/day - found no significant reduction in major cardiovascular events in primary prevention, and meta-analyses of supplemental omega-3 have generally been null or marginal. Against that, REDUCE-IT found a 25% relative reduction in events with 4 g/day icosapent ethyl in high-risk patients with elevated triglycerides on statins, while STRENGTH, using a different EPA/DHA formulation at a similar dose, found no benefit - leaving the field divided over whether the REDUCE-IT result reflects EPA specifically or the mineral oil comparator.
- titration
- Higher doses should be a medical decision, given the atrial fibrillation and bleeding signals
- starting dose
- 1,000 mg/day combined EPA+DHA with a meal, or two portions of oily fish weekly instead
Evidence
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
Abdelhamid AS, Brown TJ, Brainard JS +8 more
Increasing alpha-linolenic acid intake probably makes little or no difference to all-cause mortality or cardiovascular events, with possible small reductions in cardiovascular mortality and arrhythmia
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT)
Bhatt DL, Steg PG, Miller M +3 more
Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo.
Comparing the cardiovascular risk-reducing effects of polyunsaturated fatty acids in fish oil and krill oil: a network meta-analysis
Nguyen TT, Mafruhah OR, Huynh TTL
Krill oil lowered triglycerides and LDL cholesterol comparably to fish oil, with a possible advantage on LDL, though effect sizes were small.
Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis
Hu Y, Hu FB, Manson JE
Marine omega-3 supplementation was associated with lowered risk of myocardial infarction and coronary heart disease death.
Safety
Caveats
OTC fish oil is not equivalent to prescription EPA. Bleeding caution with anticoagulants at high doses.
Less likely to help if
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.